1
Arthrosi’s investigational gout treatment is currently being evaluated in global studies
Sobi has entered into an agreement to acquire Arthrosi Therapeutics, a private late-stage biotechnology company specialising in the development of a treatment for gout.
The acquisition will strengthen Sobi’s gout portfolio, bringing with it pozdeutinurad (AR882), an investigational once-daily oral urate transporter 1 (URAT1) inhibitor. Pozdeutinurad is currently being evaluated in two global phase 3 studies, with results expected in 2026. It is intended for the treatment of progressive and tophaceous…